Terms: = Pancreatic cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
62 results:
1. The effect of metabolism-related lifestyle and clinical risk factors on digestive system cancers in East Asian populations: a two-sample Mendelian randomization analysis.
Cai X; Li X; Liang C; Zhang M; Dong Z; Yu W
Sci Rep; 2024 Apr; 14(1):9474. PubMed ID: 38658636
[TBL] [Abstract] [Full Text] [Related]
2. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
3. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer.
Fang K; Wang J; Yuan J; Sui C; Zhi J; Xia Y; Sun M
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1952. PubMed ID: 38258341
[TBL] [Abstract] [Full Text] [Related]
4. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan.
Hiroshima Y; Kondo M; Sawada T; Hoshi SL; Okubo R; Iizumi T; Numajiri H; Okumura T; Sakurai H
Cancer Med; 2023 Oct; 12(20):20450-20458. PubMed ID: 37795771
[TBL] [Abstract] [Full Text] [Related]
6. An analysis of time to treatment in patients with pancreatic adenocarcinoma.
Sugumar K; Gendi S; Quereshy HA; Gupta S; Hue JJ; Rothermel LD; Ocuin LM; Ammori JB; Hardacre JM; Winter JM
Surgery; 2023 Jul; 174(1):83-90. PubMed ID: 37105784
[TBL] [Abstract] [Full Text] [Related]
7. Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
Kosunen TU; Nieminen AA; Kokkola A; Arkkila P; Pukkala E; Rautelin H
Helicobacter; 2023 Jun; 28(3):e12979. PubMed ID: 37009972
[TBL] [Abstract] [Full Text] [Related]
8. Apigetrin-enriched Pulmeria alba extract prevents assault of STZ on pancreatic β-cells and neuronal oxidative stress with concomitant attenuation of tissue damage and suppression of inflammation in the brain of diabetic rats.
Abdulrasheed-Adeleke T; Lawal B; Agwupuye EI; Kuo Y; Eni AM; Ekoh OF; Lukman HY; Onikanni AS; Olawale F; Saidu S; Ibrahim YO; Al Ghamdi MAS; Aggad SS; Alsayegh AA; Aljarba NH; Batiha GE; Wu ATH; Huang HS
Biomed Pharmacother; 2023 Jun; 162():114582. PubMed ID: 36989727
[TBL] [Abstract] [Full Text] [Related]
9. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis.
Zhang D; Liu J; Zheng M; Meng C; Liao J
World J Surg Oncol; 2022 Oct; 20(1):351. PubMed ID: 36309698
[TBL] [Abstract] [Full Text] [Related]
11. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some cancers in Patients With Diabetes.
Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
[TBL] [Abstract] [Full Text] [Related]
12. Oncologic management of ampullary cancer: International survey among surgical and medical oncologists.
de Jong EJM; Lemmers DHL; Benedetti Cacciaguerra A; Bouwense SAW; Geurts SME; Tjan-Heijnen VCG; Valkenburg-van Iersel LBJ; Wilmink JW; Besselink MG; Abu Hilal M; de Vos-Geelen J
Surg Oncol; 2022 Sep; 44():101841. PubMed ID: 36087543
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNAs as Indicators of Malignancy in pancreatic Ductal Adenocarcinoma (PDAC) and Cystic pancreatic Lesions.
Prinz C; Fehring L; Frese R
Cells; 2022 Aug; 11(15):. PubMed ID: 35954223
[TBL] [Abstract] [Full Text] [Related]
14. pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada.
Marfil-Garza BA; Imes S; Verhoeff K; Hefler J; Lam A; Dajani K; Anderson B; O'Gorman D; Kin T; Bigam D; Senior PA; Shapiro AMJ
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):519-532. PubMed ID: 35588757
[TBL] [Abstract] [Full Text] [Related]
15. Robotic versus open pancreaticoduodenectomy for distal cholangiocarcinoma: a multicenter propensity score-matched study.
Xu S; Zhang XP; Zhao GD; Zou WB; Zhao ZM; Hu MG; Gao YX; Tan XL; Liu Q; Liu R
Surg Endosc; 2022 Nov; 36(11):8237-8248. PubMed ID: 35534733
[TBL] [Abstract] [Full Text] [Related]
16. MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2.
Dutta M; Das B; Mohapatra D; Behera P; Senapati S; Roychowdhury A
Life Sci; 2022 Jul; 301():120592. PubMed ID: 35504332
[TBL] [Abstract] [Full Text] [Related]
17. Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B.
Hui RW; Chiu KW; Mak LY; Chang HC; Cheung KS; Fung J; Yuen MF; Seto WK
J Gastroenterol Hepatol; 2022 Jun; 37(6):1139-1147. PubMed ID: 35368120
[TBL] [Abstract] [Full Text] [Related]
18. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract] [Full Text] [Related]
19. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract] [Full Text] [Related]
20. A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
Elshami M; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Chavin KD; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2022 Aug; 24(8):1280-1290. PubMed ID: 35063353
[TBL] [Abstract] [Full Text] [Related]
[Next]
